GLAXOSMITHKLINE PHARMACEUTICALS Q2 FY27 ; NET PROFIT UP 30% AT ₹336 CR (YOY), UP 42% (QOQ)

REVENUE UP 21% AT ₹1,184 CR (YOY), UP 26% (QOQ) EBITDA UP 20% AT ₹402 CR (YOY), UP 36% (QOQ) MARGINS AT 34.0% VS 34.3% (YOY), 31.5% (QOQ)

GLAXOSMITHKLINE PHARMA LT